Mosaic adds to cancer combo pattern by licensing 2 clinical-stage drugs from Astex

Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical stage tumor drugs from fellow British biotech Astex Pharmaceuticals.

Related Posts

Time runs out for Kronos’ headquarters amid wider cost-...

Apr 11, 2025  0

Alopexx seeks $11M IPO to advance ex-Sanofi infectious ...

Feb 26, 2025  0

Abbott secures European approval for Volt pulsed field ...

Mar 27, 2025  0

Comments

Name

Email

Comment

Post Comment